Mitigation research priorities Sample Clauses

Mitigation research priorities. The Working Group identified the following PLL mitigation research priorities: Weighted branch lines: continued work to identify branch line weighting configurations (mass, placement, shape, number of leads and materials) that are effective at reducing seabird bycatch with and without other mitigation, and that are safe and practical. Bird-scaring lines: compare the effectiveness of one compared with. two bird-scaring lines; develop methods that create drag to maximise aerial extent while minimising entanglements of the in- water portion of bird-scaring lines with longline floats; and compare the effectiveness of bird-scaring lines with different steamer lengths, configurations, and materials. Also trial methods for efficient retrieval and stowage of bird scaring lines. Night setting: determine effectiveness of bird scaring lines and branch-line weighting at night by characterising seabird behaviour at night using thermal or night-vision technologies. Combinations of mitigation measures: continue to evaluate the effectiveness of pairings of the three best-practice mitigation methods (night setting, branch-line weighting and bird- scaring lines). Novel technologies: continue to develop novel technologies that release or protect baited hooks to depths beyond the reach of seabirds. Seabird “hot spots”: delineate areas of high concentrations where albatrosses and petrels are at most risk to mortality in pelagic longline fisheries and where the most rigorous seabird bycatch mitigation should be required, using bycatch rates reported by Parties as well as seabird tracking data and other data sources. It is useful also to understand which areas have least risk for albatrosses and petrels so as to avoid application of measures that fishers regard as pointless.
View Source
Mitigation research priorities. On the basis of discussions regarding mitigation research priorities for demersal longline fisheries, the Working Group identified the development and testing of mitigation measures for small vessels as the main outstanding research priority.
View Source
Mitigation research priorities. The Working Group identified the following four research areas as the highest priorities for further reducing seabird bycatch in trawl fisheries (high priority should also be given to investigating best-practice combinations of mitigation): a) options to reduce seabird interactions with warp cables by manipulating the time, nature and location of offal discharge, recognising size and operational differences between vessels; b) methods to reduce seabird becoming entangled in nets during hauling; c) methods that can be applied to various fisheries/seabird assemblages to determine relationships between seabird abundance, cable interactions and mortality; and d) the applicability of net binding across pelagic fisheries. The Working Group requested that the Advisory Committee encourages Parties and others to prioritise these areas of research and to keep the group informed of developments in relation to seabird mortality caused by trawl fisheries.
View Source

Related to Mitigation research priorities

  • Research Matters By entering into this Agreement, the Placement Agent does not provide any promise, either explicitly or implicitly, of favorable or continued research coverage of the Company and the Company hereby acknowledges and agrees that the Placement Agent’s selection as a placement agent for the Offering was in no way conditioned, explicitly or implicitly, on the Placement Agent providing favorable or any research coverage of the Company. In accordance with FINRA Rule 2711(e), the parties acknowledge and agree that the Placement Agent has not directly or indirectly offered favorable research, a specific rating or a specific price target, or threatened to change research, a rating or a price target, to the Company or inducement for the receipt of business or compensation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and, for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes materially call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Collaboration activities 4.1 The Collaboration Suppliers will perform the Collaboration Activities and all other obligations of this Agreement in accordance with the Detailed Collaboration Plan. 4.2 The Collaboration Suppliers will provide all additional cooperation and assistance as is reasonably required by the Buyer to ensure the continuous delivery of the services under the Call-Off Contract. 4.3 The Collaboration Suppliers will ensure that their respective subcontractors provide all cooperation and assistance as set out in the Detailed Collaboration Plan.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.